Blockade of intragraft IL-2 receptor- by basiliximab is insufficient to prevent activation of liver graft infiltrating cells

Author： Kwekkeboom J. Warle M.C. Rietveld J. Segeren K.C.A. Tilanus H.W. Metselaar H.J.

Publisher： Elsevier

ISSN： 0966-3274

Source： Transplant Immunology, Vol.11, Iss.1, 2003-01, pp. : 1-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An early experience with Simulect (basiliximab): an IL-2 receptor antibody

By Hinduja A. Abraham G. Eapen G. Shroff S. Rao R. Kuruvilla S.

Transplantation Proceedings, Vol. 32, Iss. 7, 2000-11 ,pp. : 1739-1740

Elsevier

Access to resources Recommend Favorite

Experience with basiliximab in pediatric liver graft recipients

By Ganschow R. Lyons M. Grabhorn E. Venzke A. Broering D.C. Rogiers X. Hellwege H.H. Burdelski M.

Transplantation Proceedings, Vol. 33, Iss. 7, 2001-11 ,pp. : 3606-3607

Elsevier

Access to resources Recommend Favorite

Blockade of killer cells can prevent lethal acute graft-versus-host disease in a rat model

By Akioka K. Okamoto M. Nakamura K. Ushigome H. Kadotani Y. Ohmori Y. Yoshimura N.

Transplantation Proceedings, Vol. 35, Iss. 1, 2003-02 ,pp. : 501-503

Elsevier

Access to resources Recommend Favorite

Apoptosis of Graft-Infiltrating Cytotoxic T Cells: A Mechanism Underlying ''Split Tolerance'' in Mouse Liver Transplantation

By Qian S. Lu L. Li Y. Fu F. Li W. Starzl T.E. Thomson A.W. Fung J.J.

Transplantation Proceedings, Vol. 29, Iss. 1, 1997-02 ,pp. : 1168-1169

Elsevier

Access to resources Recommend Favorite

IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients

By Choy B.Y. Chan T.M. Li F.K. Lui S.L. Lo W.K. Yip T. Tse K.C. Lai K.N.

Transplantation Proceedings, Vol. 35, Iss. 1, 2003-02 ,pp. : 195-195

Elsevier

Access to resources Recommend Favorite